Abstract
The objective was to assess the cost of Medication Overuse Headache (MOH) at the time-point of withdrawal treatment. We implemented a protocol in which both direct and indirect cost were directly gathered from patients and referred to the previous three months. Direct costs were calculated by medications for acute treatment and prophylaxis, diagnostic procedures, visits, complementary treatments, informal care. Indirect costs were referred to missed workdays and workdays with reduced productivity: we asked patients to refer their salaries and to rate the overall level of performance in days worked with reduced productivity, and we calculated indirect costs on this basis. A total of 135 patients were enrolled: direct costs were around 415€/month; indirect costs were 530€/month, and were mostly due to presenteeism (350€, 66.3%) rather than to absenteeism (160€, 33.7%). Our data showed higher cost than those of a previous study: this is likely due to a different approach to cost definition, to the inclusion of direct non-medical cost, and of non-pharmacological treatments.
| Original language | English |
|---|---|
| Pages (from-to) | 3-6 |
| Number of pages | 4 |
| Journal | Neurological Sciences |
| Volume | 38 |
| DOIs | |
| Publication status | Published - May 1 2017 |
Fingerprint
Keywords
- Chronic migraine
- Cost of disease
- Medication overuse
- Withdrawal
ASJC Scopus subject areas
- Dermatology
- Clinical Neurology
- Psychiatry and Mental health
Cite this
Cost of medication overuse headache in Italian patients at the time-point of withdrawal : a retrospective study based on real data. / D’Amico, Domenico; Grazzi, Licia; Curone, Marcella; Leonardi, Matilde; Raggi, Alberto.
In: Neurological Sciences, Vol. 38, 01.05.2017, p. 3-6.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cost of medication overuse headache in Italian patients at the time-point of withdrawal
T2 - a retrospective study based on real data
AU - D’Amico, Domenico
AU - Grazzi, Licia
AU - Curone, Marcella
AU - Leonardi, Matilde
AU - Raggi, Alberto
PY - 2017/5/1
Y1 - 2017/5/1
N2 - The objective was to assess the cost of Medication Overuse Headache (MOH) at the time-point of withdrawal treatment. We implemented a protocol in which both direct and indirect cost were directly gathered from patients and referred to the previous three months. Direct costs were calculated by medications for acute treatment and prophylaxis, diagnostic procedures, visits, complementary treatments, informal care. Indirect costs were referred to missed workdays and workdays with reduced productivity: we asked patients to refer their salaries and to rate the overall level of performance in days worked with reduced productivity, and we calculated indirect costs on this basis. A total of 135 patients were enrolled: direct costs were around 415€/month; indirect costs were 530€/month, and were mostly due to presenteeism (350€, 66.3%) rather than to absenteeism (160€, 33.7%). Our data showed higher cost than those of a previous study: this is likely due to a different approach to cost definition, to the inclusion of direct non-medical cost, and of non-pharmacological treatments.
AB - The objective was to assess the cost of Medication Overuse Headache (MOH) at the time-point of withdrawal treatment. We implemented a protocol in which both direct and indirect cost were directly gathered from patients and referred to the previous three months. Direct costs were calculated by medications for acute treatment and prophylaxis, diagnostic procedures, visits, complementary treatments, informal care. Indirect costs were referred to missed workdays and workdays with reduced productivity: we asked patients to refer their salaries and to rate the overall level of performance in days worked with reduced productivity, and we calculated indirect costs on this basis. A total of 135 patients were enrolled: direct costs were around 415€/month; indirect costs were 530€/month, and were mostly due to presenteeism (350€, 66.3%) rather than to absenteeism (160€, 33.7%). Our data showed higher cost than those of a previous study: this is likely due to a different approach to cost definition, to the inclusion of direct non-medical cost, and of non-pharmacological treatments.
KW - Chronic migraine
KW - Cost of disease
KW - Medication overuse
KW - Withdrawal
UR - http://www.scopus.com/inward/record.url?scp=85019571612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019571612&partnerID=8YFLogxK
U2 - 10.1007/s10072-017-2891-z
DO - 10.1007/s10072-017-2891-z
M3 - Article
AN - SCOPUS:85019571612
VL - 38
SP - 3
EP - 6
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
ER -